Cure Rates of Superficial Basal Cell Carcinoma (BCC) EDC

Not Applicable

Terminated

Brief Summary: This is a prospective, randomized clinical trial conducted at the Unviersity of Wisconsin (UW) Dermatology Clinic located at 1 S. Park Street, Madison, WI 53715. There are no controls. Subjects meeting eligibility criteria are randomly divided into one of two treatment groups (ED\&C x 1 cycle or ED\&C x 3 cycles) using computer generated random numbers. One cycle of ED\&C is defined according to standard technique currently employed. It involves scraping away the tumor with a curette (ring- shaped instrument) and then burning the curetted site with a small electric needle (electrodessication). During Visit 1, the surgical site is marked, local numbing medication is injected, and 1 or 3 cycles of ED\&C is/are performed by board-certified dermatologists or a dermatology resident under the direct supervision of a board certified dermatologist. All follow-up visits (3, 6, 9, and 12 months after Visit 1) include skin evaluations by the physician who performed the ED\&C. The lesion site is examined, measured, and photographed for clinical evidence of recurrence, as defined by a new lesion within the previously treated site. If there is evidence of possible tumor recurrence at the treated surgical site during Visit 2, 3, 4 or 5, then the lesion will be biopsied using a shave procedure.

Recruitment & Eligibility

Inclusion Criteria

Untreated, biopsy proven superficial type basal cell carcinoma (BCC-S) on the trunk and/or extremities
Age greater than 21
Women with childbearing potential (including those who are pregnant/lactating)
Able to provide written informed consent

Exclusion Criteria

Aggressive histology on initial biopsy (i.e. morpheaform, infiltrative, desmoplastic, or purely micronodular)
Prior history of BCC or other skin cancer at the same location
Lesion > 2 cm
Patients with basal cell nevus syndrome
Transplant patients
Immunocompromised patients
Recurrent BCC
Greater than 2 BCC-S on the trunk and/or extremities
Prisoners
Allergy to lidocaine or epinephrine

Primary Outcome Measures

Name	Time	Method
Difference in Cure Rates of Superficial BCC Following One Cycle of ED&C Versus Three Cycles of ED&C.	base line, every 3 months until 12 month completion	Clinical evidence of BCC recurrence post treatment

Secondary Outcome Measures

Name	Time	Method

Locations (1): University of Wisconsin-Madison, Department of Dermatology
🇺🇸
Madison, Wisconsin, United States
University of Wisconsin-Madison, Department of Dermatology
🇺🇸Madison, Wisconsin, United States